Back
Full-text
Journal article

Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019.

  • Simon D Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, dagmar.simon@insel.ch.
  • Wollenberg A Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.
  • Renz H Institute of Laboratory Medicine, Philipps University of Marburg, Marburg, Germany.
  • Simon HU Institute of Pharmacology, University of Bern, Bern, Switzerland.
Show more…
  • 2019-02-11
Published in:
  • International archives of allergy and immunology. - 2019
Anti-inflammatory therapy
Atopic dermatitis
Comorbidities
Epithelial barrier
T-helper-2 inflammation
Anti-Inflammatory Agents
Comorbidity
Dermatitis, Atopic
Humans
Receptors, Interleukin-13
Receptors, Interleukin-4
English Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. AD is determined by a genetic predisposition characterized by an impaired skin barrier and a T-helper-2-predominant inflammation. Restoration of the skin barrier is the main approach for treating and preventing AD. In order to cope with acute flares, usually topical corticosteroids (TCS) are applied, while topical calcineurin inhibitors (TCI) are used mainly for maintenance therapy. There is a small group of patients who are refractory to TCS and TCI and require systemic immunosuppressive drugs such as ciclosporin. Novel, targeted therapies are under clinical investigation, among which an anti-IL-4/IL-13 receptor antibody has recently been approved in several countries. As we learn to understand the pathomechanisms of AD, the characteristics of the different patient subgroups, and the effectiveness of various targeted therapies, a personalized treatment ensuring the best efficacy and safety and, probably, a disease-modifying effect will result.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/141036
Statistics
Document views: 46 File downloads:
  • fulltext.pdf: 0